Thanks in part to a hot new hepatitis drug called Pegasys, Roche is staging an unlikely revival, giving Chairman FranzHumer some much-needed breathing room.
Although the number given was only the total amount paid to its directors--we still had to estimate the pay of the CEO, Franz Humer--it is a step in the right direction.